Efficacy of Pentoxifylline on Chronic Kidney Disease

National Taiwan University Hospital60 enrolled

Overview

To study whether pentoxifylline has additive renoprotective effect in patients taking ARB

In patients with CKD and serum creatinine 1.3\~6.0 md/gl, having taken losartan 100 mg/day for at least 3 months, with stable renal function, will be recruited to a randomized open-label trial. Patients taking pentoxifylline or not will be compared for their spot urinary proteinuria, estimated glomerular filtration, spot urine tumor necrosis factor-α/creatinine ratio, spot urine monocyte-chemoattractant protein-1/creatinine, and aldosterone concentration between groups in a 2-year study. Add-on pentoxifylline in control group in the same dose as in treat group will be performed to observe the renoprotective effect if any protective potential is demonstrated in the end of maintenance 12 months.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Kidney Disease

Interventions

pentoxifylline (drug)DRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Chronic kidney disease with serum creatinine 1.3\~6.0 mg/dl Exclusion Criteria: * History of allergy to pentoxifylline * Females are nursing or pregnant * Obstructive uropathy * Unable to stop chronic immunosuppressive therapy, NSAID * Congestive heart failure (New York Heart Association functional class III or IV) * Unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, within the past 6 months prior to signing the informed consent form * Cerebral hemorrhage within the past 6 months prior to signing the informed consent form * Retinal hemorrhage within the past 6 months prior to signing the informed consent form * Known or suspected secondary hypertension (e.g., primary aldosteronism, renovascular hypertension, pheochromocytoma) * Severe uncontrolled hypertension with SBP \> 220 mmHg and/or DBP \> 115 mmHg * Hepatic dysfunction as defined by the following laboratory parameters: ALT or AST \> 2 times the upper limit of the normal range * Biliary obstructive disorders (e.g. cholestasis) * Active malignancy

Locations (1)

National Taiwan University Hospital

Taipei, Taiwan

Outcomes

Primary Outcomes

spot urinary proteinuria between groups

Secondary Outcomes

estimated glomerular filtration, spot urine tumor necrosis factor-α/creatinine ratio, spot urine monocyte-chemoattractant protein-1/creatinine, and aldosterone concentration between groups.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.